Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter July 8, 2011

Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study

Stanislava Koloušková, Daniela Zemková, Jana Bartošová, Veronika Skalická, Zdeněk Šumník, Věra Vávrová and Jan Lebl

Abstract

Cystic fibrosis related diabetes (CFRD) is an insulinopenic condition. We aimed to detect insulinopenia early and to evaluate the impact of low dose insulin on nutritional status and forced expiratory volume in first second (FEV1). Out of 142 cystic fibrosis patients (CFpts) older than 10 years, 28 with abnormal oral glucose tolerance test in spite of normal fasting glycemia were found to have decreased first phase insulin release and started low dose insulin therapy (median age 15.4 years). Sex and age matched CFpts with normal glucose tolerance (NGT) were observed for comparison. Whereas nutritional status improved following 3 years of insulin administration, FEV1 stabilized in insulin-treated insulinopenic subjects (73.8±4.3% vs. 73.5±4.4%), but decreased in the parallel group with NGT who remained without insulin treatment (71.1±3.8% vs. 61.0±4.0%; p=0.001). We conclude that low dose insulin improves nutritional status and stabilizes pulmonary functions. Regular estimation of stimulated insulin secretion in CFpts may allow optimizing treatment.


Corresponding author: Prof. Jan Lebl, MD, PhD, Department of Pediatrics, Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, CZ-150 06 Praha 5, Czech Republic Phone: +420 224 432 001, Fax: +420 224 432 020

Published Online: 2011-07-08
Published in Print: 2011-08-01

©2011 by Walter de Gruyter Berlin Boston

Scroll Up Arrow